NMPA Proposes Revisions to “Drug Inspection Management Measures”, Seeks Public Feedback
The National Medical Products Administration (NMPA) has released revised provisions of the “Drug Inspection Management...
Henlius Biotech Suspends IPO on STAR Market, Aims to Optimize Capital Strategy
Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced the suspension of its initial public...
Shanghai’s Huangpu District Launches RMB Fund to Boost Fintech, AI, and Biotech Firms
The South China Morning Post reports that the local government in Shanghai’s Huangpu district has...
Transcenta’s Osemitamab Combo Shows Promising PFS Data in Advanced GC/GEJ Cancer Study
Transcenta Holding Ltd (HKG: 6628), a China-based biopharmaceutical company, has presented progression-free survival (PFS) data...
Hybio Pharmaceutical’s Liraglutide Biosimilar Withdrawn from NMPA Filing
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced that the National Medical Products Administration...
Sinotau Pharmaceutical Secures Over RMB 1.1 Billion in Latest Financing Round
Sinotau Pharmaceutical Group, a prominent nuclear medicine (radiopharmaceutical) company headquartered in Beijing, has reportedly raised...
Innovent Biologics and IASO Biotherapeutics’ Fucaso Approved for Multiple Myeloma Treatment in China
Innovent Biologics, Inc. (HKG: 1801) and IASO Biotherapeutics have announced that they have received marketing...
SciClone Pharmaceuticals’ Danyelza Officially Launched in China for Neuroblastoma Treatment
SciClone Pharmaceuticals Inc. (Nasdaq: SCLN) has reached a significant milestone with the first prescription of...
Zai Lab’s Vyvgart Receives NMPA Approval as First-in-Class FcRn Antagonist for Myasthenia Gravis
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a China-based biopharmaceutical company, has announced that the...
InnoCare Pharma and Keymed Biosciences Initiate Clinical Trial for ICP-B02 with First Subcutaneous Injection
InnoCare Pharma (HKG: 9969; SHA: 688428) and Keymed Biosciences Inc., (HKG: 2162) have announced a...
Jiangsu Hengrui Medicine Gets NMPA Approval for HRS-4357 Clinical Study in Prostate Cancer
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading China-based pharmaceutical company, has announced that...
Sichuan Biokin Pharmaceutical Gets FDA Approval for BL-B01D1 Clinical Study
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...
RareStone Group’s Pitolisant Earns Priority Review Status for Narcolepsy Treatment in China
The Center for Drug Evaluation (CDE) website in China has indicated that RareStone Group, a...
Joincare Pharmaceutical Initiates Phase III Study for Anti-IL-17A mAb in Plaque Psoriasis
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced the initiation of a...
Bio-heart’s Iberis-HTN Study Shows Promising Results in Treating Primary Hypertension
China-based Bio-heart Biological Technology Co., Ltd. (HKG: 2185) and its holding subsidiary Angiocare have announced...
Sisram Medical’s Alma Lasers Acquires PhotonMed International Ltd, Expanding Global Presence
Sisram Medical Ltd (HKG: 1696), an Israel-based company and part of the Fosun Pharmaceutical Group...
Beijing Sun-Novo and Zhejiang Anglikang Enter Licensing Agreement for Hypertension Drug Candidate NHKC-1
Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced a significant licensing agreement with...
ZSP1273 by Guangdong Zhongsheng Pharma Shows Promise in Phase III Flu Treatment Study
Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a China-based pharmaceutical company, has announced preliminary top-line...
Hansoh Pharmaceutical’s Phenylheptal Peptide Receives NMPA Approval for Anemia Treatment
The National Medical Products Administration (NMPA) has issued a marketing approval for China-based Hansoh Pharmaceutical...
Sinocelltech Group Receives NMPA Approval for Bevacizumab Biosimilar for Multiple Cancers
China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received marketing approval from...